BioSpectrum
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

PrecizionIQ: Making Prenatal Diagnostics More Accessible Through Metabolomics

23 October 2026 | Features

Founded in 2022, the company is using metabolomics and advanced analytical technologies to improve prenatal screening, with an initial focus on chromosomal abnormalities and preeclampsia. Its long-term ambition is to extend its diagnostic platform to other diseases, including cancer.



Problem

Prenatal screening plays a critical role in identifying chromosomal abnormalities and pregnancy-related complications, but access to advanced diagnostic tests can be constrained by cost, infrastructure and the need for specialised testing. PrecizionIQ aims to make early risk detection more affordable and accessible through non-invasive, biomarker-based

diagnostic solutions.

Product

PrecizionIQ is developing metabolomics-based prenatal diagnostics using three formats: dried blood spot testing analysed through liquid chromatography–mass spectrometry (LC-MS), ELISA-based laboratory testing and lateral flow assay (LFA) rapid tests. The company aims to combine the analytical depth of advanced diagnostics with simpler, lower-cost testing formats for wider adoption.

Proof

The startup has filed a Patent Cooperation Treaty (PCT) application for its metabolomics-based diagnostic methodology for prenatal chromosomal abnormalities. In 2026, it also secured a Golden Ticket at the PanIIT Bangalore Summit's Bharat Ke Super Founders pitchathon, gaining recognition for its diagnostic innovation. Its products remain at the development and validation stage, based on publicly available information.

People

PrecizionIQ's founding team includes Dr. Murli Manohar, Dr. Pedro Rodrigues, Dr. Kamal Tyagi, Amit Kumar and Anurag Dikshit. The team brings together expertise directed towards developing biomarker-led diagnostic technologies and translating scientific research into accessible healthcare solutions.

Purse

PrecizionIQ has reported securing $210,000 in pre-seed funding from a US-based angel investor to support product development, clinical validation and regulatory groundwork. The company is currently reported to be pre-revenue, with funding directed towards advancing its diagnostic platform towards commercialisation.

Plan

The immediate priority is to commercialise its prenatal diagnostic solutions for chromosomal abnormalities and preeclampsia, subject to clinical validation and regulatory requirements. The company also plans to explore partnerships with diagnostic laboratories and healthcare providers, while extending its metabolomics platform to areas such as cancer detection.

Why it matters:

PrecizionIQ is working to bridge the gap between advanced biomarker science and affordable prenatal screening. If successfully validated and commercialised, its diagnostic formats could help extend access to early risk assessment across hospitals, diagnostic laboratories and underserved communities.

FAST FACTS

Category	Details
Company	PrecizionIQ Data Private Limited
HQ	Gurugram, Haryana
Founded	September 2022
Industry	Biotechnology, precision diagnostics
Founders	Dr. Murli Manohar, Dr. Pedro Rodrigues, Dr. Kamal Tyagi, Amit Kumar and Anurag Dikshit

Core technology	Metabolomics-based biomarker profiling
Lead focus	Prenatal chromosomal abnormalities and preeclampsia
Test formats	LC-MS, ELISA and lateral flow assay
Latest reported funding	$210,000 pre-seed funding
Key milestone	PCT patent application filed; Golden Ticket at PanIIT Bangalore Summit 2026
Current stage	Research, development and clinical validation
Next	Advance validation, commercialise prenatal tests and explore new diagnostic applications

Disclaimer: This profile is independent editorial content based on publicly available information and company disclosures reviewed as of October 2026. The profile does not constitute medical, clinical or investment advice.